BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/14/2025 10:52:07 AM | Browse: 102 | Download: 374
 |
Received |
|
2025-04-07 09:40 |
|
Peer-Review Started |
|
2025-04-16 09:01 |
|
First Decision by Editorial Office Director |
|
2025-04-24 02:46 |
|
Return for Revision |
|
2025-04-24 02:46 |
|
Revised |
|
2025-05-08 15:16 |
|
Publication Fee Transferred |
|
2025-05-10 16:23 |
|
Second Decision by Editor |
|
2025-06-17 02:48 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-07-02 09:11 |
|
Articles in Press |
|
2025-07-02 09:11 |
|
Edit the Manuscript by Language Editor |
|
2025-07-17 21:04 |
|
Typeset the Manuscript |
|
2025-08-04 02:59 |
|
Publish the Manuscript Online |
|
2025-08-14 10:52 |
| ISSN |
1948-9358 (online) |
| Open Access |
Diabetic cystopathy (DCP), a debilitating complication of diabetes mellitus, involves hyperglycemia-driven bladder dysfunction. This study identified CREB3 L3 as a novel mediator of DCP pathogenesis. Chronic hyperglycemia induced CREB3 L3 overexpression in bladder urothelium, promoting C-reactive protein-dependent inflammation, epithelial-mesenchymal transition (EMT) and tight junction disruption. Silencing CREB3 L3 in SV-HUC-1 urothelial cells and a DCP rat model reversed EMT markers (downregulation of N-cadherin and upregulation of E-cadherin protein), restored barrier proteins (Occludin/Claudin1 protein), and attenuated bladder remodeling. These findings have established CREB3 L3 as a therapeutic target to preserve urothelial integrity and mitigate DCP progression. |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Basic Study |
| Article Title |
Hyperglycemia-induced overexpression of CREB3 L3 promotes the epithelial-to-mesenchymal transition in bladder urothelial cells in diabetes mellitus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qing-Guo Wu, Ming-Jin Zhang, Yi-Bi Lan, Chun-Lei Ma and Wei-Jin Fu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| GuangXi Natural Science Foundation |
2024GXNSFAA010031 |
|
| Corresponding Author |
Wei-Jin Fu, Chief Physician, Department of Urology, The First Affiliated Hospital of GuangXi Medical University, No. 6 Shuangyong Road, Qinxiu District, Nanning 530022, Guangxi Zhuang Autonomous Region, China. fwjgxmu1978@163.com |
| Key Words |
Hyperglycemia; Epithelial-mesenchymal transition; Diabetic cystopathy |
| Core Tip |
Diabetic cystopathy (DCP), a debilitating complication of diabetes mellitus, involves hyperglycemia-driven bladder dysfunction. This study identified CREB3 L3 as a novel mediator of DCP pathogenesis. Chronic hyperglycemia induced CREB3 L3 overexpression in bladder urothelium, promoting C-reactive protein-dependent inflammation, epithelial-mesenchymal transition (EMT) and tight junction disruption. Silencing CREB3 L3 in SV-HUC-1 urothelial cells and a DCP rat model reversed EMT markers (downregulation of N-cadherin and upregulation of E-cadherin protein), restored barrier proteins (Occludin/Claudin1 protein), and attenuated bladder remodeling. These findings have established CREB3 L3 as a therapeutic target to preserve urothelial integrity and mitigate DCP progression. |
| Publish Date |
2025-08-14 10:52 |
| Citation |
Wu QG, Zhang MJ, Lan YB, Ma CL, Fu WJ. Hyperglycemia-induced overexpression of CREB3 L3 promotes the epithelial-to-mesenchymal transition in bladder urothelial cells in diabetes mellitus. World J Diabetes 2025; 16(8): 108101 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i8/108101.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i8.108101 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
